Persistent digital hyperthermia over a 48 h period does not induce laminitis in horses.
Persistent digital hyperthermia, presumably due to vasodilation, occurs during the developmental and acute stages of insulin-induced laminitis. The objectives of this study were to determine if persistent digital hyperthermia is the principal pathogenic mechanism responsible for the development of laminitis. The potent vasodilator, ATP-MgCl(2) was infused continuously into the distal phalanx of the left forefoot of six Standardbred racehorses for 48 h via intra-osseous infusion to promote persistent digital hyperthermia. The right forefoot was infused with saline solution and acted as an internal control. Clinical signs of lameness at the walk were not detected at 0 h, 24h or 48 h post-infusion. Mean ± SE hoof wall temperatures of the left forefoot (29.4 ± 0.25°C) were higher (P<0.05) than those on the right (27.5 ± 0.38°C). Serum insulin (15.0 ± 2.89 μIU/mL) and blood glucose (5.4 ± 0.22 mM) concentrations remained unchanged during the experiment. Histopathological evidence of laminitis was not detected in any horse. The results demonstrated that digital vasodilation up to 30°C for a period of 48 h does not trigger laminitis in the absence of hyperinsulinaemia. Thus, although digital hyperthermia may play a role in the pathogenesis of laminitis, it is not the sole mechanism involved.
Australian Equine Laminitis Research Unit, School of Veterinary Science, The University of Queensland, Gatton, Queensland 4343, Australia. m.delaat@uq.edu.au
Melody A
MA
de Laat
Christopher C
CC
Pollitt
Donald M
DM
Walsh
Catherine M
CM
McGowan
Martin N
MN
Sillence
D000255:Adenosine Triphosphate / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D005534:Foot Diseases / Q000150:complications / Q000662:veterinary*; D005552:Forelimb; D006724:Hoof and Claw; D006734:Horse Diseases / Q000209:etiology*; D006736:Horses; D006358:Hot Temperature / Q000009:adverse effects*; D007249:Inflammation / Q000150:complications / Q000662:veterinary*; D017148:Infusions, Intraosseous; D008297:Male; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects
D014665:Vasodilator Agents; D000255:Adenosine Triphosphate